Toshi Takeuchi
About Toshi Takeuchi
Toshi Takeuchi is the CSO with a Ph.D. in Chemistry from Caltech and over 20 years of experience in antibody expression, therapeutic discovery, and development.
Professional Title and Role
Toshi Takeuchi serves as the Chief Scientific Officer (CSO). He is responsible for overseeing scientific research and guiding the organization's scientific strategy and operations. His leadership plays a pivotal role in advancing the company’s therapeutic discovery and development efforts.
Education and Expertise in Chemistry
Toshi Takeuchi earned his Ph.D. in Chemistry from the California Institute of Technology in 1996. His extensive educational background has provided him with a solid foundation in chemistry, which he has leveraged throughout his career in the field of antibody expression and engineering, as well as therapeutic discovery and development.
Industrial Experience in Antibody Engineering
With over 20 years of industrial experience, Toshi Takeuchi has worked in various capacities across the biotechnology sector. His experience includes roles at small startups and large multinational corporations like Bioren (acquired by Pfizer) and Bayer. His extensive background encompasses antibody expression and engineering, crucial for developing therapeutic solutions.
Leadership Roles in Discovery Research
Toshi Takeuchi has held significant leadership roles, including serving as the Vice President of Discovery Research at XOMA Corporation. At XOMA, he was responsible for the selection, engineering, and characterization of multiple antibodies that reached clinical development. He has also contributed to the development of therapeutics derived from the human microbiome as the VP of Discovery Research at Second Genome.
Personal Interests and Hobbies
Outside of his professional life, Toshi Takeuchi enjoys several hobbies, including cycling, playing the violin, gardening, meditating, and spending time with his family. These activities provide him with a balanced lifestyle and a means to unwind from his demanding role in the biotechnology industry.